Loading...
Please wait, while we are loading the content...
Similar Documents
Association between the efficacy of fluoxetine treatment in obsessive–compulsive disorder patients and SLC1A1 in a Han Chinese population
| Content Provider | Semantic Scholar |
|---|---|
| Author | Zhang, Kai Cao, Leiming Wang, Guoqiang Zhao, M. Z. |
| Copyright Year | 2015 |
| Abstract | Obsessive–compulsive disorder (OCD) is a chronic psychiatric disorder characterized by obsessions and/or compulsions that cause distress or interfere with functioning. Most OCD patients receive drug therapy and psychotherapy, but the efficacy of OCD treatment is not satisfactory. Fluoxetine, a selective serotonin reuptake inhibitors, is a common drug for the therapy of OCD, but there is individual difference in therapy efficacy. Pharmacogenetics studies show that some genotypes of glutamate transporter gene SLC1A1 significantly associated with OCD therapy efficacy (Zai et al., 2013). In this study, we selected two SNPs rs301430 and 3780412 of SLC1A1 to verify the association between SLC1A1 and the response of a cohort of OCD patients of Han Chinese ethnicity to fluoxetine treatment. In this case-control study, 340 OCD patients and 350 healthy controls were included. Diagnoses were made by two or more trained psychiatrists using the MINI, a simple, structured diagnostic interview designed to provide DSM-IV diagnoses of axis I psychiatric disorders. The patients met the lifetime DSM-IV diagnostic criteria for OCD based on a structured interview. The exclusion criteria included: age less than 18 years; a history of substance use and other major mental illnesses; unable to clarify the histories of other diseases. All subjects were Han Chinese, subjects were excluded if three or four grandparents were of non-Chinese ancestry, had no consanguinity to any participants, and signed informed consent forms. The study protocol and procedures were assessed and approved by the ethics committee of the Wuxi Mental Health Center. After obtaining informed consent, blood samples were collected from the OCD patients and the healthy controls. Severity of obsessive–compulsive symptoms, baseline and after a 12-week therapy, which was scored using the Yale–Brown Obsessive– Compulsive Scale (Y-BOCS), were assessed by trained raters blinded to genotypes. In order to enhance the reliability, the measurements of Y-BOCS were confirmed by a parent or companion of patients. All OCD patients used fluoxetine daily, consisting of 20 mg/day as the initial dose and an increase to the therapeutic dose (40– 60 mg/day) after 3–7 days. Patients with severe symptoms of anxiety or poor sleep were allowed to take 2 mg/day estazolam tablets during the first two weeks of therapy but were asked to stop using estazolam after two weeks. To exclude confounding factors of fluoxetine therapy efficacy, the patients taking any other |
| Starting Page | 631 |
| Ending Page | 632 |
| Page Count | 2 |
| File Format | PDF HTM / HTML |
| DOI | 10.1016/j.psychres.2015.06.039 |
| PubMed reference number | 26154820 |
| Journal | Medline |
| Volume Number | 229 |
| Alternate Webpage(s) | https://api.elsevier.com/content/article/pii/S0165178115004400 |
| Alternate Webpage(s) | https://www.sciencedirect.com/science/article/pii/S0165178115004400?dgcid=api_sd_search-api-endpoint |
| Alternate Webpage(s) | https://doi.org/10.1016/j.psychres.2015.06.039 |
| Journal | Psychiatry Research |
| Language | English |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Article |
